The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Open Access
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 16 (1) , e223-e231
Abstract
No abstract availableKeywords
Funding Information
- Bayer HealthCare
This publication has 49 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- The expression of androgen‐responsive genes is Up‐Regulated in the epithelia of benign prostatic hyperplasiaThe Prostate, 2009
- The postchemotherapy PSA surge syndromeAnnals of Oncology, 2008
- Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate CancerClinical Cancer Research, 2006
- Prostate specific antigen gene regulation by androgen receptorJournal of Cellular Biochemistry, 2004